How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/transthyretin-familial-amyloid-polyneuropathy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Transthyretin familial amyloid polyneuropathy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transthyretin familial amyloid polyneuropathy (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Transthyretin familial amyloid polyneuropathy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Amvuttra	VUTRISIRAN	Alnylam Pharmaceuticals	Small Interfering RNA	transthyretin (TTR) mRNA	2022-01-01
Onpattro	PATISIRAN	Alnylam Pharmaceuticals	Small Interfering RNA	transthyretin (TTR) mRNA	2018-01-01
Onpattro	PATISIRAN SODIUM	Alnylam Pharmaceuticals	Small Interfering RNA	transthyretin (TTR) mRNA	2018-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Alnylam Pharmaceuticals · 3 drugs in Transthyretin familial amyloid polyneuropathy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Transthyretin familial amyloid polyneuropathy:

Cite this brief

Drug Landscape (2026). Transthyretin familial amyloid polyneuropathy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/transthyretin-familial-amyloid-polyneuropathy. Accessed 2026-06-10.

Transthyretin familial amyloid polyneuropathy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing